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D2 Receptor Blockade by Flunarizine and Cinnarizine Explains Extrapyramidal Side Effects. A SPECT Study
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The striatal dopamine D 2 receptor-binding potential was determined and found to be reduced by 14 to 63% (39. 5 ± 15.0%; p < 0.0001) in patients compared with age matched control values. This reduction was larger in 12 patients with extrapyramidal symptoms and was only slowly reversible after discontinuation of treatment. Pa-Flunarizine (Fz) and cinnarizine (Cz) are calcium channel blockers with actions on the T-, L-, and N-type calcium channels (Pauwels et aI., 1991) , which are widely used in Europe and South Amer ica for the treatment of migraine, vertigo, and cere brovascular disorders. These substances are piper azine derivatives with a chemical structure resem bling the neuroleptic trifluoperazine, and have been shown to have sedative actions on the vestibular labyrinth and to decrease whole blood viscosity (Godfraind et aI., 1982; Micheli et aI., 1989) . These actions provided the rationale for their use in pa tients with dizziness and vascular disease. It is also postulated that Fz has a neuroprotective effect (Pauwels et aI., 1991) . For several years it has been known that Fz and Cz can produce parkinsonian symptoms (Chouza et aI., 1986) . Although a dopa mine receptor blocking effect of Fz has been de-tients treated for >6 months had significantly larger re ductions than patients treated for a shorter period. Par kinsonian symptoms were only seen in patients older than 50 years. Our findings prove a neuroleptic-like action of Fz and Cz, which seems to be the major reason for their extrapyramidal side effects. Older age and long-term treatment are predisposing factors for these effects. Key Words: Cinnarizine-Dopamine D 2 receptors-Extra pyramidal side effects-Flunarizine-Iodobenzamide SPECT.
scribed in experimental studies (Ambrosio and Ste fanini, 1991) , the pathomechanism of these side effects is still under discussion. Moreover, interac tions with the dopaminergic system at the presyn aptic level have also been reported (Garcia-Ruiz et aI., 1992a) . Considering that all these results are based on animal experiments, we were interested in studying the effects of Fz and Cz in humans in vivo and in measuring dopamine D2 receptor binding with single-photon emission computed tomography (SPECT) in patients treated with these substances.
METHODS

Patients and controls
We examined 26 patients (19 women, 7 men), aged 22-77 years (56.7 ± 19.4), treated with Fz (22 patients) or Cz (four patients). The daily dose of Fz was 10 mg in 19 patients, S mg in two, and 15 mg in one patient, that of Cz 150 mg (three patients) and 225 mg (one patient), respec tively. The duration of therapy ranged from 2 weeks to 4 years (14.3 ± 14.1 months). The indication for adminis tration of Fz or Cz was migraine in 13 patients, vertigo and tinnitus in 8, and unspecified cerebrovascular insuf ficiency in five patients. One patient already suffered from Parkinson's disease before she was treated with 225 mg cinnarizine daily by her general practitioner and was studied with SPECT before and 1 month after initiation of this treatment (patient 12 from Table 1). One patient with migraine was also studied before and 2 months after start ing on 10 mg of Fz daily (patient 3 from Table 1 ). All patients underwent at least one clinical neurologic exam ination which was performed either on the day or within one week of the SPECT study. Parkinsonian symptom atology was rated according to the Unified Parkinson's Disease Rating Scale (UPDRS, motor examination, and activities of daily living) (Fahn et ai., 1987) , and the se verity of symptoms was classified according to Hoehn and Yahr (1967) chosen for data collection. The camera heads were equipped with low-energy, all purpose collimators so as to reduce scatter; therefore, the multiple energy window technique for scatter correction did not need to be ap plied. Scanning modalities and image processing have been described in detail (Podreka et ai., 1989; BIiicke et ai., 1991a) . After reconstruction of the images, the con secutive summation of five transverse sections gave a set of 15.6-mm-thick transverse slices. From these, one slice was chosen where the striatum was best visualized. Ir regular ROls were drawn in the left and right striatum and in the left and right frontal cortex with an average size of 40 pixels by one and the same examiner. CT or MRI images helped to define the anatomic boundaries of the striatum. Because of the very low density of cortical D 2 receptors, the frontal ROI is considered to represent non specifically bound and free radioactivity, the striatal ROI total bound plus free (Seibyl et ai., 1992) . Left and right frontal ROls were pooled together and the average counts/pixel were calculated. Counts in the striatum were calculated in several consecutive overlapping 15.6-mm thick slices, each shifted by 3.125 mm parallel to the can tomeatal plane and the slice with the highest count rate for each striatum was used, so as to avoid tilting errors. Finally, a ratio between striatal and average cortical counts/pixel was calculated. Considering that the mea surements are performed with tracer amounts of the ligand at binding equilibrium and that the amount of non specifically bound and free radioactivity is equal in the striatal and frontal ROI, which is indicated by the fact that the uptake of the inactive isomer of S(-)IBZM, i.e., R( + )IBZM, was found to be the same in these two re-gions (Briicke et al., 1991 a) , this ratio minus one corre sponds to the so-called "binding potential" (Brna) Kd).
This binding potential was compared with the age matched control value obtained from the regression anal ysis of the control group. In two patients who had been studied before and after starting treatment, the pretreat ment value was taken as control. Results are given as percentage reduction of this control value and express the rate of receptor occupancy by either Fz or Cz. For statistical analysis we used Student's t test (two tailed).
RESULTS
Clinical findings
The neurologic examination revealed normal findings in 13 patients and parkinsonian signs in 12. Bradykinesia and rigidity were prominent in eight of these patients and tremor was the main symptom in four. The severity of symptoms varied between stage 1 and 3 according to Hoehn and Yahr (1967) in 11 patients. One patient who already suffered from Parkinson's disease before the onset of treatment worsened from stage 3 to stage 5 after taking 225 mg Cz for 1 month (patient 12 from Table 1). One pa tient had hemiparesis. All patients with parkinso nian symptoms were older than 50 years and the age difference between patients with and without ex trapyramidal symptoms was highly significant (70.1 ± 8.7 years vs. 45.2 ± 18.6 years; p = 0.0003).
SPECT findings
A highly significant decline of dopamine D2 re ceptor binding with increasing age was found in the control group and was calculated by linear regres sion to be �0.5% per year (p = 0.0001; Fig. 1 ). This is in line with our previous findings (Briicke et al., 1991) and with recent positron emission tomogra phy (PET) data, which demonstrated a decline of [ 1I C]raclopride binding of 0.6% per year in the puta men (Antonini et al., 1993) . frontal cortex ratio minus 1) in 21 normal controls. A highly significant decrease of D2 binding with increasing age is seen (�0.5% per year; p = 0.0001).
D2 receptor binding, expressed as a percentage of the age-matched control value, was reduced in all patients under Fz or Cz treatment without any ex ception (Fig. 2) . The extent of the reduction ranged from 14 to 63% (39.5 ± 15.0%; p < 0.0001). Patients treated for more than 6 months had significantly larger reductions than patients treated for a shorter period (47.0 ± 13.4% vs. 32.0 ± 12.9%; n = 13 in each group; p = 0.008). Also, an age of >50 years was associated with a larger reduction (43.6 ± 13.2% vs. 31.8 ± 15.9%; n = 17 and 9, respectively; p = 0.054). The presence of parkinsonian symp toms was associated with a significantly larger re duction of D2 receptor binding (46.0 ± 13.6% vs. 33.9 ± 14.3%; n = 12 and 14, respectively; p = 0.038). No correlation was found between the se verity of symptoms and the degree of this reduc tion.
A clear-cut dosage-response relation could not be established because only two patients were given 5 mg, 19 patients 10 mg, and one patient 15 mg of Fz, and only one patient received 225 mg of Cz and three patients 150 mg of Cz.
Follow-up studies
In one parkinsonian patient, D2 receptor binding was first in the lower normal range and was found to be decreased by 50% after a 1 month treatment with 225 mg of Cz; this ran parallel to a worsening of her clinical condition from stage 3 to 5 according to Hoehn and Yahr (1967) (patient 12 from Table 1 ). In one migraine patient, D2 receptor binding was first within normal range and decreased by 48% after treatment with 10 mg Fz daily for 2 months. Her clinical examination remained normal (patient 3 from Table O . The time course of D2 receptor blockade after discontinuation of treatment with 150 mg cinnarizine daily for 24 months and 10 mg flunarizine daily for 24 and 36 months, respectively, in three patients with extrapyramidal symptoms is shown in Fig. 3 (patients 16, 24, and 25 from Table  1 ). The slow recovery of D2 binding ran parallel to a slow disappearance of extrapyramidal symptoms. No parkinsonian signs could be detected at the time of the last SPECT scan.
DISCUSSION
Measurement of S(-)IBZM binding to dopamine receptors with SPECT has been shown to give a reliable index of striatal D2 receptor density or oc cupancy rate by different neuroleptics in vivo (Briicke et al., 1991a,b; Brilcke et al., 1992) . A very similar approach for the determination of the D2 receptor occupancy rate has been used by Farde and co-workers with [ ll C]raciopride and PET (Farde et al., 1992) . We have used the IBZM- iii N C 0.2 SPECT method to examine a possible neuroleptic like action of the calcium channel blockers Fz and Cz in humans in vivo. It has been described re cently that Fz inhibits eHlspiperone binding to rat striatal membranes with similar potency as sulpiride (Ambrosio et aI., 1991) . Previous reports had also suggested an antidopaminergic action of Fz in be havioral studies (Grebb, 1986 ). An increase in pro lactin levels after Fz treatment in patients with mi graine also pointed towards a neuroleptic-like effect (Bonuccelli et aI., 1988) . However, a recent study on Cz-induced parkinsonism in primates suggested a predominant presynaptic effect on dopaminergic neurons with a decrease of cerebrospinal fluid lev els of homovanillic acid, which is explained by a , 1992a) . The present study shows for the first time that the calcium channel blockers Fz and Cz markedly block striatal dopamine D2 receptors in humans at dosages that are clinically used. In some cases, this blockade reaches a magnitude that is compara ble to that seen after treatment with neuroleptics. It is further shown that the degree of this receptor blockade correlates with the occurrence of parkin sonian symptoms, which makes it probable that this is the major action underlying these side effects. Follow up studies in three patients after discontin uation of treatment prove that the neuroleptic-like action of Fz and Cz can last for months. This ex plains the clinical observation that recovery from calcium channel blocker induced parkinsonism is slow and usually takes several months (Garcia-Ruiz et aI., 1992b) . That this long-lasting decrease in D2 receptor binding is due to a decreased synthesis rate of dopamine receptors induced by the calcium blocking actions of Fz and Cz on a protein kinase dependent mechanism is unlikely because chronic treatment with the calcium channel blocker nifed ipine does not cause a decrease in S(-)IBZM bind ing in humans (unpublished observations from our group). It is also unlikely that the underlying dis eases the patients had been treated for account for changes in D2 receptor binding. Because of ethical reasons only one of the younger migraine patients could be studied before and after treatment with Fz, and showed normal receptor binding in the pretreat ment study. In three of the older patients treated with Fz or Cz for vertigo a recovery of S(-)IBZM binding was found after discontinuation of treat ment, indicating that it is drug treatment and not the underlying disease that is responsible for the find-ings. In a recent PET study by Carson et al. (1993) , it was shown that equilibrium measurement with reversible receptor ligands, as in the present study, can produce biased receptor estimates due to changes in plasma clearance rates. These errors are smaller, however, when tissue ratios are used in stead of plasma input curves. It cannot be excluded that Fz or Cz did influence S(-)IBZM plasma clear ance in the patient group, thereby producing some error in the binding estimates because plasma count rates were not measured in the present study. Fu ture experiments will have to address this issue. In the present study, the largest effects were seen dur ing long-term treatment (>6 months). This could be due to an accumulation of these drugs.
It is interesting that parkinsonian symptoms only appeared in aged patients (>50 years), although this finding and the finding of a somewhat larger reduc tion of striatal D2 receptor binding in patients >50 years of age might have been biased by a longer duration of treatment with Fz or Cz in this group. A possible explanation for the larger reduction in pa tients older than 50 years might be a slower metab olism and excretion rate with increasing age, which might also lead to an accumulation of these drugs. The measured reduction of striatal D2 receptor binding in patients with parkinsonian symptoms av eraged 46% compared with age-matched controls. In young patients under neuroleptic treatment, it has been shown that a receptor blockade of -75% is necessary for the development of parkinsonian side effects (Farde et al., 1992) . However, together with the age-related loss of D2 receptors of -5% per de cade, the receptor blockade measured in the older patients reported here adds to a larger absolute loss of D2 binding in comparison with the group of younger patients, who did not develop extrapyrami dal side effects. In combination with the well known progressive loss of dopamine in the nigro striatal system in old age (Carlsson and Winblad, 1976) , this might explain why older patients are more likely to develop parkinsonism after Fz or Cz treatment. It is also possible that some of these pa tients actually had a preclinical form of Parkinson's disease with a loss of striatal dopamine still below the threshold for overt clinical symptoms, in whom the disease was unmasked by the D2 receptor block ade caused by Fz or Cz. These are further reasons why chronic treatment with these substances should be discouraged, especially in older patients. This has already been suggested (Micheli et al., 1989) .
It seems likely that the observed D2 receptor blockade by Fz and Cz is the major reason for the development of parkinsonism. However, it cannot be excluded that other mechanisms, such as a pre synaptic effect with decreased synthesis or release of dopamine, might also be involved (Fadda et al., 1989 , Garcia-Ruiz et al., 1992a .
